Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,290 across all filing types
Latest filing 2021-04-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物关于向控股股东借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction where the company plans to borrow funds from its controlling shareholder. It details the terms of the loan, the approval process by the board, and the need for shareholder approval at the upcoming annual general meeting. The document is relatively short (2131 characters) and focuses on the disclosure of a financing transaction involving related parties. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. It is a formal announcement of a capital/financing update related to borrowing and related party transactions. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-04-22 Chinese
安图生物第三届监事会第十九次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhengzhou Antu Bioengineering Co., Ltd. It details the outcomes of the 19th meeting of the 3rd Supervisory Board, including approvals of various reports and proposals related to the 2020 fiscal year and 2021 plans. The document includes voting results on items such as the 2020 Supervisory Board Work Report, 2020 Financial Final Report, 2021 Financial Budget Report, profit distribution proposals, and other governance matters. It also references that these items will be submitted to the 2020 Annual General Meeting for approval. The document is a formal announcement of meeting resolutions and voting results rather than the reports themselves. It is relatively short (3337 characters) and repeatedly states that the proposals will be submitted to the shareholders' meeting for approval. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-04-22 Chinese
安图生物2021年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告正文' which translates to '2021 First Quarter Report Main Text'. It contains detailed financial data including balance sheet items, profit and loss statement, cash flow statement, and explanations of financial changes for the first quarter of 2021. The document length is over 6000 characters, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is an annual report, audit report, or other filing types. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2021-04-22 Chinese
安图生物关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard effective from January 1, 2021. It details the nature of the accounting policy change, its impact on financial statements, and the approval process by the board and supervisory committees. The document is relatively short (2207 characters) and does not contain actual financial statements or substantive financial data. It is a formal disclosure about an accounting policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2021-04-22 Chinese
招商证券股份有限公司关于郑州安图生物工程股份有限公司2020年持续督导年度报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "2020 年持续督导年度报告书" which translates to "2020 Annual Continuous Supervision Report" by the sponsor (招商证券股份有限公司) for the company 郑州安图生物工程股份有限公司. It details the continuous supervision work done by the sponsor during 2020, including review of fundraising activities, compliance with regulations, information disclosure, and internal controls. The document includes detailed descriptions of the supervision process, findings, and confirmations that no violations or irregularities occurred during the period. It is not a full annual report of the company, nor is it an earnings release or a proxy statement. It is a regulatory report related to the sponsor's ongoing supervision duties as required by securities regulators. The document length is 4499 characters, which is relatively short but contains substantive content about supervision activities and compliance. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance and supervision report submitted to regulators and stock exchanges, not a financial report or announcement of voting results or capital changes.
2021-04-22 Chinese
安图生物2020年度募集资金存放与使用情况专项审核报告
Regulatory Filings
2021-04-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.